IMC-1121B
| IMC-1121B | |
|---|---|
| Term | IMC-1121B |
| Short definition | IMC-1121B - A drug that binds to the protein vascular endothelial growth factor (VEGF) to prevent the formation of new blood vessels and is used to treat various types of cancer. It is used alone or with other medicines to treat certain types of non-small cell lung cancer, hepatocellular carcinoma (a type of liver cancer), colon cancer, stomach cancer and cancer of the gastro-oesophageal junction. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
IMC-1121B - A drug that binds to the protein vascular endothelial growth factor (VEGF) to prevent the formation of new blood vessels and is used to treat various types of cancer. It is used alone or with other medicines to treat certain types of non-small cell lung cancer, hepatocellular carcinoma (a type of liver cancer), colon cancer, stomach cancer and cancer of the gastro-oesophageal junction. It is also being studied in the treatment of other types of cancer. IMC-1121B can prevent the growth of new blood vessels that tumors need to grow. It's a type of anti-angiogenesis drug and a type of monoclonal antibody. Also referred to as fully human anti-VEGFR-2 monoclonal antibody IMC-1121B, Cyramza and Ramucirumab
External links
- Medical encyclopedia article on IMC-1121B
- Wikipedia's article - IMC-1121B
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski